RxDoctor Payments Data

Robert Grossberg, MD

Infectious Disease · Bronx, NYNPI 1538259338

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Theratechnologies Inc. at 51.6% of the total. Reporting peaked in 2020 at $2,685 and has fallen 99.1% since, to $24 in 2023.

$2,906in general payments, 2019–2025

Across 22 payments — averaging $132.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theratechnologies Inc.$2K
  • Merck$1K
  • AbbVie$254
  • Gilead$24
$1,036,672in research payments, 2019–2025

Across 427 payments — averaging $2427.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$360K
  • Gilead$320K
  • GSK$127K
  • Merck$98K
  • AbbVie$60K
  • Amgen$38K
  • plus $33K from 1 others

What the payments were for

  • Speaking & faculty fees$1,50052%
  • Travel & lodging$77627%
  • Food & beverage$63022%

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Theratechnologies Inc.1$1,500
Merck11$1,128
AbbVie9$254
Gilead1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,906 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$26,726
Medicare patients
138
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala289$1,107,157
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf136$640,680
TivicayDolutegravir Sodium97$222,359
GenvoyaElviteg/Cob/Emtri/Tenof Alafen44$173,743
DescovyEmtricitabine/Tenofov Alafenam63$131,016
OdefseyEmtricitab/Rilpiviri/Tenof Ala35$121,346
PrezcobixDarunavir/Cobicistat50$116,774
RukobiaFostemsavir Tromethamine12$101,349
DovatoDolutegravir Sodium/Lamivudine29$79,894
TriumeqAbacavir/Dolutegravir/Lamivudi21$76,282
EliquisApixaban57$36,914
OzempicSemaglutide30$26,645
JardianceEmpagliflozin36$24,649
EvotazAtazanavir Sulfate/Cobicistat16$24,065
PifeltroDoravirine12$19,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$24$1,411,916396 claims
MerckPifeltro$1,128$19,80512 claims
AbbVieSynthroid$254$49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.

Other infectious disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →